drugset / Trial / NCT01082198
Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes
Open-labelTreatment
Summary
RATIONALE: Vaccines made from dendritic cells and tumor antigen peptides or a person's tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best way to give melanoma vaccine in treating patients with stage III melanoma after surgery to remove the lymph nodes.
Timeline
- Start
- 2002-10
- Primary completion
- 2010-04
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine | Vaccine | — | Subcutaneous |
| Subject | MART-1 antigen | Vaccine | — | Subcutaneous |
| Subject | autologous melanoma lysate-pulsed autologous dendritic cell vaccine | Vaccine | — | Subcutaneous |
| Subject | autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine | Vaccine | — | Subcutaneous |
| Subject | dendritic cell-idiotype-keyhole limpet hemocyanin vaccine | Vaccine | — | Subcutaneous |